Aptevo Q3 2023 net loss $6.3M; cash $19.1M; funding extends runway into Q4 2024

Aptevo Therapeutics Inc.

2023-Q3 EPS reported -$1.28

Net loss of $6.3M ($0.50 per share) vs $7.6M loss in Q3 2022; no revenue reported.
Cash and equivalents $19.1M at Sept 30; raised $7M via public offering and warrant exercises, with potential additional $9.2M.
R&D expenses $3.9M (down $0.6M); G&A $2.7M (down $0.6M) year-over-year.
ALG.APV-527 Phase 1 dose-escalation trial for solid tumors continues enrolling patients; APVO436 Phase 2 planning ongoing.
Cash runway expected into Q4 2024, allowing reach of clinical milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptevo Therapeutics Inc. reported the quarter ended September 30, 2023 results: net income net loss of $6.3 million or $0.50 per share, EPS $0.50 per share.

Period: the quarter ended September 30, 2023
Net income: net loss of $6.3 million or $0.50 per share
EPS: $0.50 per share
Result: reported results

Exact text from the filing

Aptevo had a net loss of $6.3 million or $0.50 per share for the three months ended September 30, 2023, compared to a net loss of $7.6 million or $1.50 per share for the corresponding period in 2022.

View on SEC.gov

Browse all earnings releases →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-063369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.